Tag: Efflux transporters

Over 98% of small molecule drugs and virtually 100% of large molecule drugs cannot effectively cross the blood-brain barrier (BBB). This highly selective blockade necessitates a deeper understanding of what is the main mode of transport of drugs across the blood-brain barrier, which varies significantly depending on the drug's properties.

Approximately 98% of small-molecule drugs fail to cross the blood-brain barrier (BBB), making central nervous system (CNS) diseases incredibly difficult to treat. Modern pharmacology is leveraging the very mechanisms of this protective barrier to facilitate targeted delivery of drugs to the brain, using advanced engineering to overcome its natural resistance.

An estimated 98% of small-molecule drugs and virtually all large-molecule drugs fail to cross the blood-brain barrier (BBB), posing a major challenge in developing medications for neurological disorders. Understanding what makes a drug cross the blood-brain barrier is therefore central to modern pharmacology and therapeutic development.